NCT02743546 2025-02-03Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaJanssen Research & Development, LLCPhase 1 Withdrawn